Compare CHMG & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | PROK |
|---|---|---|
| Founded | 1833 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.9M | 359.4M |
| IPO Year | 1995 | 2021 |
| Metric | CHMG | PROK |
|---|---|---|
| Price | $85.30 | $1.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $92.35 | $7.88 |
| AVG Volume (30 Days) | 50.7K | ★ 1.3M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.36 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $31.95 | N/A |
| Revenue Next Year | $7.35 | N/A |
| P/E Ratio | $13.38 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $50.31 | $0.87 |
| 52 Week High | $89.34 | $2.65 |
| Indicator | CHMG | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 33.21 |
| Support Level | $79.30 | $0.87 |
| Resistance Level | $89.34 | $2.01 |
| Average True Range (ATR) | 2.04 | 0.15 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 31.64 | 23.43 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.